Journal of Neural Transmission

, Volume 113, Issue 9, pp 1107–1118 | Cite as

Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture

  • G. Gille
  • K. Radad
  • H. Reichmann
  • W.-D. Rausch
Article

Summary.

There is an ongoing controversy about potential toxicity of L-3,4-dihydroxyphenylalanine (L-dopa) to dopaminergic neurons in Parkinson’s disease (PD). Neuroimaging data suggest that L-dopa accelerates the loss of dopamine nerve terminals, especially at higher doses. The disputed aspect of toxicity and the frequently observed motor complications accompanying L-dopa therapy have led to an increased use of dopamine agonists during the past two decades. Reports describing their neuroprotective potential to dopaminergic neurons have attracted much attention. Here, we describe the novel finding that the combination of a dopamine (DA) agonist, α-dihydroergocryptine (DHEC), with L-dopa or DA exerts a synergistic stimulatory effect on dopaminergic neurons in primary culture, while each substance alone had no or less effect. DA receptor stimulation plays a decisive role. The synergistic effect suggests that a combinatory therapy can be beneficial to slow the degeneration of dopaminergic neurons.

Keywords: α-Dihydroergocryptine, L-dopa, dopamine, synergism, dopaminergic neurons. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albanese, A, Colosimo, C 2003Dihydroergocriptine in Parkinson’s disease: clinical efficacy and comparison with other dopamine agonistsActa Neurol Scand107349355PubMedCrossRefGoogle Scholar
  2. Alexander, T, Sortwell, CE, Sladek, CD, Roth, RH, Steece-Collier, K 1997Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donorsCell Transplant6309315PubMedCrossRefGoogle Scholar
  3. Asanuma, M, Miyazaki, I, Ogawa, N 2003Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s diseaseNeurotox Res5165176PubMedCrossRefGoogle Scholar
  4. Bal, A, Bachelot, T, Savasta, M, Manier, M, Verna, JM, Benabid, AL, Feuerstein, C 1994Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studiesBrain Res Mol Brain Res23204212PubMedCrossRefGoogle Scholar
  5. Basma, AN, Morris, EJ, Nicklas, WJ, Geller, HM 1995L-dopa cytotoxicity to PC12 cells in culture is via its autoxidationJ Neurochem64825832PubMedCrossRefGoogle Scholar
  6. Battino, M, Littarru, GP, Gorini, A, Villa, RF 1996Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson’s-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptineNeurochem Res2115051514PubMedGoogle Scholar
  7. Bergamasco, B, Frattola, L, Muratorio, A, Piccoli, F, Mailland, F, Parnetti, L 2000Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled studyActa Neurol Scand101372380PubMedCrossRefGoogle Scholar
  8. Bernocchi, G, Gerzeli, G, Scherini, E, Vignola, C 1993Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineActa Neuropathol (Berl)85404413CrossRefGoogle Scholar
  9. Bindoli, A, Rigobello, MP, Deeble, DJ 1992Biochemical and toxicological properties of the oxidation products of catecholaminesFree Radic Biol Med13391405PubMedCrossRefGoogle Scholar
  10. Blessing, H, Bareiss, M, Zettlmeisl, H, Schwarz, J, Storch, A 2003Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicityNeurochem Int42139151PubMedCrossRefGoogle Scholar
  11. Cassarino, DS, Fall, CP, Smith, TS, Bennett, JP,Jr 1998Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ionJ Neurochem71295301PubMedCrossRefGoogle Scholar
  12. Coppi, G 1995Neuroprotective activity of alpha-dihydroergocryptine in animal modelsJ Neural Transm [Suppl]45307318Google Scholar
  13. Engele, J, Bohn, MC 1991The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic gliaJ Neurosci1130703078PubMedGoogle Scholar
  14. Engele, J, Schubert, D, Bohn, MC 1991Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: role of mesencephalic gliaJ Neurosci Res30359371PubMedCrossRefGoogle Scholar
  15. Fahn, S, Oakes, D, Shoulson, I, Kieburtz, K, Rudolph, A, Lang, A, Olanow, CW, Tanner, C, Marek, K 2004Levodopa and the progression of Parkinson’s diseaseN Engl J Med35124982508PubMedCrossRefGoogle Scholar
  16. Fahn, S, Przedborski, S 2000

    Parkinsonism

    Rowland, LP eds. Merritt’s neurologyLippincott Williams & WilkinsNew York679693
    Google Scholar
  17. Favit, A, Sortino, MA, Aleppo, G, Scapagnini, U, Canonico, PL 1995The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptineJ Neural Transm [Suppl]45297305Google Scholar
  18. Foley, P, Gerlach, M, Double, KL, Riederer, P 2004Dopamine receptor agonists in the therapy of Parkinson’s diseaseJ Neural Transm11113751446PubMedCrossRefGoogle Scholar
  19. Gerlach, M, Double, K, Arzberger, T, Leblhuber, F, Tatschner, T, Riederer, P 2003Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatumJ Neural Transm11011191127PubMedCrossRefGoogle Scholar
  20. Gille, G, Rausch, WD, Hung, ST, Moldzio, R, Janetzky, B, Hundemer, HP, Kolter, T, Reichmann, H 2002aPergolide protects dopaminergic neurons in primary culture under stress conditionsJ Neural Transm109633643CrossRefGoogle Scholar
  21. Gille, G, Rausch, WD, Hung, ST, Moldzio, R, Ngyuen, A, Janetzky, B, Engfer, A, Reichmann, H 2002bProtection of dopaminergic neurons in primary culture by lisurideJ Neural Transm109157169CrossRefGoogle Scholar
  22. Gluck, MR, Zeevalk, GD 2004Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson’s disease and catecholamine-associated diseasesJ Neurochem91788795PubMedCrossRefGoogle Scholar
  23. Gomez-Santos, C, Ferrer, I, Santidrian, AF, Barrachina, M, Gil, J, Ambrosio, S 2003Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cellsJ Neurosci Res73341350PubMedCrossRefGoogle Scholar
  24. Graham, DG 1978Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinonesMol Pharmacol14633643PubMedGoogle Scholar
  25. Grunblatt, E, Mandel, S, Maor, G, Youdim, MB 2001Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal lossJ Neurochem77146156PubMedCrossRefGoogle Scholar
  26. Gu, M, Irvani, M, Cooper, JM, King, D, Jenner, P, Schapira, AH 2004Pramipexole protects against apoptotic cell death by non-dopaminergic mechanismsJ Neurochem9110751081PubMedCrossRefGoogle Scholar
  27. Han, SK, Mytilineou, C, Cohen, G 1996L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stressJ Neurochem66501510PubMedCrossRefGoogle Scholar
  28. Iida, M, Miyazaki, I, Tanaka, K, Kabuto, H, Iwata-Ichikawa, E, Ogawa, N 1999Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonistBrain Res8385159PubMedCrossRefGoogle Scholar
  29. Joyce, JN, Woolsey, C, Ryoo, H, Borwege, S, Hagner, D 2004Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptorBMC Biol222PubMedCrossRefGoogle Scholar
  30. Junghanns, S, Glockler, T, Reichmann, H 2004Switching and combining of dopamine agonistsJ Neurol251VI/19VI/23CrossRefGoogle Scholar
  31. Kitamura, Y, Kosaka, T, Kakimura, JI, Matsuoka, Y, Kohno, Y, Nomura, Y, Taniguchi, T 1998Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cellsMol Pharmacol5410461054PubMedGoogle Scholar
  32. Lamensdorf, I, Eisenhofer, G, Harvey-White, J, Hayakawa, Y, Kirk, K, Kopin, IJ 2000Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehydeJ Neurosci Res60552558PubMedCrossRefGoogle Scholar
  33. Le, WD, Jankovic, J 2001Are dopamine receptor agonists neuroprotective in Parkinson’s disease?Drugs Aging18389396PubMedCrossRefGoogle Scholar
  34. Ling, ZD, Pieri, SC, Carvey, PM 1996Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin Neuropharmacol19360365PubMedCrossRefGoogle Scholar
  35. Ling, ZD, Robie, HC, Tong, CW, Carvey, PM 1999Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic culturesJ Pharmacol Exp Ther289202210PubMedGoogle Scholar
  36. Maher, P, Schubert, D 2000Signaling by reactive oxygen species in the nervous systemCell Mol Life Sci5712871305PubMedCrossRefGoogle Scholar
  37. Mailland, E, Magnani, P, Ottillinger, B 2004Alpha-dihydroergocriptine in the long-term therapy of Parkinson’s diseaseArzneimittelforschung54647654PubMedGoogle Scholar
  38. Mena, MA, Casarejos, MJ, Carazo, A, Paino, CL, Garcia, DY 1996Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicityNeuroreport7441445PubMedGoogle Scholar
  39. Mena, MA, Casarejos, MJ, Carazo, A, Paino, CL, Garcia, DY 1997aGlia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanismsJ Neural Transm104317328CrossRefGoogle Scholar
  40. Mena, MA, Davila, V, Bogaluvsky, J, Sulzer, D 1998A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factorMol Pharmacol54678686PubMedGoogle Scholar
  41. Mena, MA, Davila, V, Sulzer, D 1997bNeurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte coculturesJ Neurochem6913981408CrossRefGoogle Scholar
  42. Mena, MA, Pardo, B, Paino, CL, De Yebenes, JG 1993Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acidNeuroreport4438440PubMedGoogle Scholar
  43. Miyazaki, I, Asanuma, M, Diaz-Corrales, FJ, Miyoshi, K, Ogawa, N 2004Direct evidence for expression of dopamine receptors in astrocytes from basal gangliaBrain Res1029120123PubMedCrossRefGoogle Scholar
  44. Muralikrishnan, D, Mohanakumar, KP 1998Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in miceFASEB J12905912PubMedGoogle Scholar
  45. Mytilineou, C, Han, SK, Cohen, G 1993Toxic and protective effects of L-dopa on mesencephalic cell culturesJ Neurochem6114701478PubMedGoogle Scholar
  46. O’Malley, EK, Sieber, BA, Black, IB, Dreyfus, CF 1992Mesencephalic type I astrocytes mediate the survival of substantia nigra dopaminergic neurons in cultureBrain Res5826570PubMedCrossRefGoogle Scholar
  47. Ogawa, N, Tanaka, K, Asanuma, M, Kawai, M, Masumizu, T, Kohno, M, Mori, A 1994Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitroBrain Res657207213PubMedCrossRefGoogle Scholar
  48. Olanow, CW 1992An introduction to the free radical hypothesis in Parkinson’s diseaseAnn Neurol32S2S9PubMedCrossRefGoogle Scholar
  49. Olanow, CW, Agid, Y, Mizuno, Y, Albanese, A, Bonucelli, U, Damier, P, De Yebenes, J, Gershanik, O, Guttman, M, Grandas, F, Hallett, M, Hornykiewicz, O, Jenner, P, Katzenschlager, R, Langston, WJ, LeWitt, P, Melamed, E, Mena, MA, Michel, PP, Mytilineou, C, Obeso, JA, Poewe, W, Quinn, N, Raisman-Vozari, R, Rajput, AH, Rascol, O, Sampaio, C, Stocchi, F 2004Levodopa in the treatment of Parkinson’s disease: current controversiesMov Disord199971005PubMedCrossRefGoogle Scholar
  50. Pardo, B, Mena, MA, Casarejos, MJ, Paino, CL, De Yebenes, JG 1995Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidantsBrain Res682133143PubMedCrossRefGoogle Scholar
  51. Parkinson Study Group2002Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progressionJAMA28716531661CrossRefGoogle Scholar
  52. Pedrosa, R, Soares-da-Silva, P 2002Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamineBr J Pharmacol13713051313PubMedCrossRefGoogle Scholar
  53. Pelton, EW, Kimelberg, HK, Shipherd, SV, Bourke, RS 1981Dopamine and norepinephrine uptake and metabolism by astroglial cells in cultureLife Sci2816551663PubMedCrossRefGoogle Scholar
  54. Pirtosek, Z, Flisar, D 2004Neuroprotection and dopamine agonistsAdv Exp Med Biol5415574PubMedGoogle Scholar
  55. Przedborski, S, Jackson-Lewis, V, Muthane, U, Jiang, H, Ferreira, M, Naini, AB, Fahn, S 1993Chronic levodopa administration alters cerebral mitochondrial respiratory chain activityAnn Neurol34715723PubMedCrossRefGoogle Scholar
  56. Reichmann, H, Herting, B, Miller, A, Sommer, U 2003Switching and combining dopamine agonistsJ Neural Transm11013931400PubMedCrossRefGoogle Scholar
  57. Reuss, B, Unsicker, K 2000Survival and differentiation of dopaminergic mesencephalic neurons are promoted by dopamine-mediated induction of FGF-2 in striatal astroglial cellsMol Cell Neurosci16781792PubMedCrossRefGoogle Scholar
  58. Rodriguez-Martin, E, Canals, S, Casarejos, MJ, de Bernardo, S, Handler, A, Mena, MA 2001L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cellsJ Neurochem78535545PubMedCrossRefGoogle Scholar
  59. Sampaio-Maia, B, Serrao, MP, Soares-da-Silva, P 2001Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cellsAm J Physiol Cell Physiol280C333C342PubMedGoogle Scholar
  60. Sauer, H, Wartenberg, M, Hescheler, J 2001Reactive oxygen species as intracellular messengers during cell growth and differentiationCell Physiol Biochem11173186PubMedCrossRefGoogle Scholar
  61. Schapira, AH 2003Neuroprotection in PD-A role for dopamine agonists?Neurology61S34S42PubMedGoogle Scholar
  62. Schinelli, S, Paolillo, M, Quartieri, M, Santagostino, G 1993Dopamine synthesis, uptake and metabolism in embryonic rat mesencephalic culturesPharmacol Res28265276PubMedCrossRefGoogle Scholar
  63. Seeman, P, Van Tol, HH 1994Dopamine receptor pharmacologyTrends Pharmacol Sci15264270PubMedCrossRefGoogle Scholar
  64. Spencer, JP, Jenner, P, Daniel, SE, Lees, AJ, Marsden, DC, Halliwell, B 1998Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen speciesJ Neurochem7121122122PubMedCrossRefGoogle Scholar
  65. Spencer, JP, Whiteman, M, Jenner, P, Halliwell, B 20025-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neuronsJ Neurochem81122129PubMedCrossRefGoogle Scholar
  66. Spina, MB, Cohen, G 1989Dopamine turnover and glutathione oxidation: implications for Parkinson diseaseProc Natl Acad Sci USA8613981400PubMedCrossRefGoogle Scholar
  67. Stern, MB 2004Dopamine agonists modify the course of Parkinson diseaseArch Neurol6119691971PubMedCrossRefGoogle Scholar
  68. Takashima, H, Tsujihata, M, Kishikawa, M, Freed, WJ 1999Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptorsExp Neurol15998104PubMedCrossRefGoogle Scholar
  69. Tsai, MJ, Lee, EH 1996Characterization of L-DOPA transport in cultured rat and mouse astrocytesJ Neurosci Res43490495PubMedCrossRefGoogle Scholar
  70. Weingarten, P, Bermak, J, Zhou, QY 2001Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidantsJ Neurochem7617941804PubMedCrossRefGoogle Scholar
  71. Whone, AL, Watts, RL, Stoessl, AJ, Davis, M, Reske, S, Nahmias, C, Lang, AE, Rascol, O, Ribeiro, MJ, Remy, P, Poewe, WH, Hauser, RA, Brooks, DJ 2003Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET studyAnn Neurol5493101PubMedCrossRefGoogle Scholar
  72. Zhou, J, Bradford, HF, Stern, GM 1996Induction of dopaminergic neurotransmitter phenotype in rat embryonic cerebrocortex by the synergistic action of neurotrophins and dopamineEur J Neurosci823282339PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • G. Gille
    • 1
  • K. Radad
    • 2
  • H. Reichmann
    • 1
  • W.-D. Rausch
    • 2
  1. 1.Department of NeurologyTechnical UniversityDresdenGermany
  2. 2.Institute for Medical ChemistryVeterinary Medical UniversityViennaAustria

Personalised recommendations